Liver Dysfunction in Sepsis

0
358

Roohealthcare.com – In septic patients, about one-third of the patients will have some degree of liver dysfunction. However, current diagnostic tools do not readily identify early insults. Liver dysfunction can range from subclinical injury to overt failure. Liver dysfunction in sepsis is usually divided into two categories: hypoxic hepatitis and jaundice. In most cases, liver failure is considered a late complication of sepsis, which can be prevented by identifying the underlying causes.

Considerations Helping Adjustment of Drugs with Liver Dysfunction

Fortunately, some basic considerations can help guide the dosage adjustment in patients with liver dysfunction. While many medications have a therapeutic range, there are many variables that can create a false need for some drugs. For example, some patients with mild or moderate liver disease may not need a large dose at first, so starting low and gradually increasing the dosage can be a good strategy. In addition, if drug levels are not known or are not characterized by a well-established therapeutic range, patients should be monitored for side effects and to determine their appropriateness.

Bilirubin, a by-product of the enzymatic breakdown of heme, is produced in the liver. Unconjugated bilirubin is quickly transported into the bile and does not appear in the bloodstream until the liver loses half of its excretory capacity. Moreover, the conjugated level of bilirubin in the serum does not increase until the liver is functioning at less than half of its capacity.

The liver is responsible for the storage of up to 20% of the body’s weight in fat and glucose. Glucogen, a form of simple sugar, is metabolized by the liver in order to store it. This fuel is then reconverted to glucose when needed. This process is a slow and constant one. When a person suffers from NAFLD, their liver responds to an epinephrine release and releases large quantities of fuel into the blood.

Liver Check by Performing Multiple Tests

Biliary obstruction, or blockage of bile ducts, leads to lack of bile flow. The bile ducts are blocked by certain types of disease, such as liver failure, and AP and GGT levels rise to several times the normal range. AP elevations in the liver are often greater than 1,000 U per L or more than six times the normal levels. Infiltrative diseases cause the highest AP elevations.

In addition to palpation, liver inspection includes auscultation and percussion. These procedures are often performed in the right midclavicular line and can give valuable information about the liver’s functioning. Abnormal results in either of these two methods may indicate cirrhosis, hepatitis, or bilirubin. Some liver tests can also identify patients who have bleeding esophageal varices.

UDCA improves liver function by altering relevant microbiome composition and improving metabolic pathways. It also exerts antioxidant effects similar to vitamin E. This treatment may therefore prove beneficial in cases of liver failure. In a recent study, UDCA significantly decreased miR-122 levels in the liver and improved liver function scores. This study is the first to test a bile acid supplement as a treatment for liver failure.

Treatment for Acute Liver Failure

The treatment for acute liver failure depends on the severity of hepatic encephalopathy. In cases of grade one hepatic encephalopathy, patients may be managed on the medical floor. However, patients with grade two and three should be admitted to the intensive care unit. If this condition progresses to grade four, patients may require mechanical ventilation, intubation, or liver transplantation. Acute renal failure is the most common cause of liver encephalopathy, which can require surgery.

Hepatic disease may cause ALF, as can malignancy. Malignancy may cause multiple hepatic metastases or diffuse infiltration of malignant cells. Although primary hepatic malignancies are rare, they may be the cause of ALF. It is also possible for ALF to occur in patients who have undergone ischemia, such as in Budd Chiari syndrome, prolonged systemic hypotension, or sepsis.

Reference:

Yan, Jun, Song Li, and Shulin Li. “The role of the liver in sepsis.” International reviews of immunology 33.6 (2014): 498-510.

Capussotti, L., Viganò, L., Giuliante, F., Ferrero, A., Giovannini, I., & Nuzzo, G. (2009). Liver dysfunction and sepsis determine operative mortality after liver resection. Journal of British Surgery96(1), 88-94.

LEAVE A REPLY

Please enter your comment!
Please enter your name here